XOMA (NASDAQ:XOMA) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a research report report published on Friday morning.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $104.00 price objective on shares of XOMA in a research report on Wednesday, March 19th.

XOMA Trading Down 0.9 %

Shares of XOMA stock opened at $20.88 on Friday. The stock has a market capitalization of $250.12 million, a PE ratio of -6.00 and a beta of 1.00. XOMA has a 1-year low of $19.92 and a 1-year high of $35.00. The business has a 50-day moving average of $24.37 and a 200 day moving average of $27.12. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The business had revenue of $8.70 million during the quarter, compared to analysts’ expectations of $8.75 million. As a group, sell-side analysts anticipate that XOMA will post -1.41 earnings per share for the current year.

Insider Activity at XOMA

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a filing with the SEC, which is available through this link. 7.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On XOMA

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its stake in shares of XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares during the last quarter. New York State Common Retirement Fund boosted its position in XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 800 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of XOMA by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 1,183 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 2,009 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in XOMA in the 4th quarter worth $206,000. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.